Free Trial

Laboratory Co. of America (LH) Stock Forecast & Price Target

Laboratory Co. of America logo
$233.55 -2.89 (-1.22%)
As of 03:58 PM Eastern

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
11

Based on 14 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 3 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$269.92
15.57% Upside
According to the 14 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $269.92. The highest price target for LH is $300.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 15.57% from the current price of $233.55.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Laboratory Co. of America and its competitors.

Sign Up

LH Analyst Ratings Over Time

TypeCurrent Forecast
3/25/24 to 3/25/25
1 Month Ago
2/24/24 to 2/23/25
3 Months Ago
12/26/23 to 12/25/24
1 Year Ago
3/26/23 to 3/25/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$269.92$265.31$258.62$243.50
Forecasted Upside15.57% Upside6.18% Upside12.69% Upside13.92% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Remove Ads

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Laboratory Co. of America Stock vs. The Competition

TypeLaboratory Co. of AmericaMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside15.26% Upside21,744.19% Upside17.40% Upside
News Sentiment Rating
Positive News

See Recent LH News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/4/2025Citigroup
3 of 5 stars
Ralph Giacobbe
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$250.00 ➝ $300.00+18.11%
2/10/2025Piper Sandler
2 of 5 stars
D. Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$240.00 ➝ $260.00+5.79%
2/7/2025Barclays
3 of 5 stars
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$271.00 ➝ $260.00+5.61%
2/6/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tycho Peterson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$275.00 ➝ $290.00+17.25%
1/28/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$293.00 ➝ $286.00+14.61%
1/7/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$260.00 ➝ $265.00+15.42%
12/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $270.00+17.38%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$262.00 ➝ $271.00+16.67%
10/30/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$282.00 ➝ $289.00+25.61%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$220.00 ➝ $230.00-2.35%
8/2/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $275.00+18.79%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$261.00 ➝ $243.00+25.49%
3/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$250.00+17.23%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$260.00+18.63%
10/31/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$257.00 ➝ $230.00+16.07%
8/14/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$290.00 ➝ $270.00+23.85%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$247.41 ➝ $231.00+8.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:51 PM ET.


Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 23, 2025. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • Recent upgrades from multiple analysts, including Citigroup raising the target price to $300.00, indicate strong market confidence in the company's growth potential.
  • The stock currently trades at $233.97, which is below the average target price of $268.38, suggesting potential for price appreciation.
  • Laboratory Co. of America Holdings has reported a solid earnings per share (EPS) of $3.45, exceeding expectations, which reflects strong operational performance.
  • With a market capitalization of $19.58 billion and a PE ratio of 26.53, the company shows a healthy balance between growth and valuation, appealing to growth-oriented investors.
  • Insider trading activity, such as recent purchases by Representative April McClain Delaney, can signal confidence in the company's future prospects.

Laboratory Co. of America
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • Insider selling, including a significant sale by CEO Adam H. Schechter, may raise concerns about the company's future performance and insider confidence.
  • The company has a debt-to-equity ratio of 0.67, which, while manageable, indicates some level of financial leverage that could pose risks in a downturn.
  • Despite recent positive earnings, the stock has experienced fluctuations, with a 12-month high of $258.59, suggesting volatility that may deter risk-averse investors.
  • Analysts have mixed ratings, with three holding a neutral stance, which may indicate uncertainty about the company's long-term growth trajectory.
  • The current market environment may present challenges, as broader economic factors can impact the healthcare sector, potentially affecting Laboratory Co. of America Holdings' performance.

LH Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $269.92, with a high forecast of $300.00 and a low forecast of $230.00.

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LH shares.

According to analysts, Laboratory Co. of America's stock has a predicted upside of 15.57% based on their 12-month stock forecasts.

Over the previous 90 days, Laboratory Co. of America's stock had 2 upgrades by analysts.

Laboratory Co. of America has been rated by research analysts at Barclays, Citigroup, Evercore ISI, Jefferies Financial Group, Piper Sandler, and UBS Group in the past 90 days.

Analysts like Laboratory Co. of America more than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.86 while the average consensus rating score for "medical" companies is 2.82. Learn more on how LH compares to other companies.


This page (NYSE:LH) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners